Selinexor (KPT-330), an Oral Selective Inhibitor of Nuclear Export (SINE) Compound, in Combination with FOLFOX in Patients with Metastatic Colorectal Cancer (mCRC) - Final Results of the Phase I Trial SENTINEL.

CONCLUSION: In patients with metastatic colorectal cancer, selinexor on this dose schedule plus mFOLFOX6 was not tolerable. Other dosing schedules or combinations may be evaluated. Clinical trial identifier NCT02384850. PMID: 32598257 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/32598257?dopt=Abstract

Source: Current Cancer Drug Targets - June 26, 2020 Category: Cancer & Oncology Authors: Nilsson S, Stein A, Rolfo C, Kranich A, Mann J, Papadimitriou K, Theile S, Amberg S, Bokemeyer C Tags: Curr Cancer Drug Targets Source Type: research